Those findings led us to investigate the expression levels of RAP1 in low- and high-grade CIN lesions to address the potential use of this putative oncogene as a cervical neoplasia biomarker. The gene discussed is RAP1A; the disease is cervical squamous intraepithelial neoplasia.